Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...

Dr. Mubita joins board certified neurosurgeon Dr. Joshua Anderson and advanced practitioners Caelan Brazee and Tina Stringham. Their practice at 908 N. Howard Ave., Suite 108, is ...

Diseases of the nervous system refer to disorders that affect any part of the central nervous system (brain, spinal cord or cranial nerves) or peripheral nervous system. A hallmark of addiction is ...

The development of drugs to treat major diseases of the central nervous system relies in part on the development of novel strategies to cross the blood brain barrier. Michel Khrestchatisky and ...

Audiologist and researcher Dr. Julia Campbell shares her insights into the state of misophonia research and how we may get ...

Research reveals how your daily coffee could be amplifying anxiety symptoms, with genetic factors determining who's most at ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to dem ...

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

Researchers have found a unique molecular signature and genes in the orbitofrontal cortex associated with heroin-seeking behavior. A preclinical rodent model implicated a gene called Shisa7 as the key ...

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY. GOTHENBURG, SE / ACCESS Newswire / March 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a comp ...

Learn how nanoparticles cross the blood-brain barrier (BBB) and explore their potential in treating neurological disorders ...

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) will likely be releasing its earnings data after the market closes on ...